Application of euglena and euglena product in improvement of hyperuricemia

Abstract

The invention discloses application of euglena and a product thereof to improvement of hyperuricemia. The euglena and the product thereof are used for improving the hyperuricemia. The euglena and the product thereof improve hyperuricemia by reducing uric acid and protecting the kidney from uric acid damage. The uric acid reducing effect of the euglena and the euglena product and the uric acid reducing effect of the medicine febuxostat have a superposed effect According to the euglena and the euglena product, intestinal flora is regulated by promoting probiotic flora in the intestinal tract and inhibiting growth of harmful flora in the intestinal tract, catabolism of purine and uric acid in the intestinal tract is promoted, and uric acid metabolism is regulated. The euglena and products thereof include euglena and euglena polysaccharides. The invention provides a new method for treating people with hyperuricemia. The euglena and the euglena polysaccharide improve hyperuricemia by reducing uric acid and protecting kidneys from being damaged by uric acid, regulate intestinal flora by promoting probiotic flora in intestinal tracts and inhibiting growth of harmful flora in the intestinal tracts, promote catabolism of purine and uric acid in the intestinal tracts and regulate uric acid metabolism.

Description

Technical Field

[0001] The present invention relates to the technical field of functional foods, in particular to application of euglena and products thereof in improving hyperuricemia. Background Art

[0002] With rapid economic development, people's economic status has gradually improved. An increasingly abundant diet has led to an increased intake of high-protein and high-fat foods, which in turn increases the risk of many diseases, such as hyperuricemia (gout). Hyperuricemia has become the second most common metabolic disease in my country, second only to diabetes. It can cause joint disease and is associated with cancer, hypertension, and diabetes, posing a serious threat to people's health. Hyperuricemia is caused by the fact that during human metabolism, purines produced by the degradation of nucleic acids and ingested from food are converted to hypoxanthine by the enzyme adenosine aminotransferase (ADA). Hypoxanthine is then converted to xanthine by the enzyme xanthine oxidase (XOD), ultimately producing uric acid. When uric acid production exceeds the body's excretion capacity, or when excretion decreases, uric acid accumulates, leading to hyperuricemia, which requires medication. The mode of action of drugs is to inhibit uric acid production or promote uric acid excretion. For example, allopurinol and febuxostat mainly inhibit uric acid production by inhibiting the activity of XOD, while benzbromarone and probenecid promote uric acid excretion by inhibiting the reabsorption of uric acid by the renal tubules. However, these drugs often have obvious side effects when used clinically, such as allergies, liver and kidney dysfunction, etc. Therefore, the development of a functional food that is safe, effective and can quickly improve hyperuricemia has certain social significance.

[0003] Euglena gracilis, also known as Euglena or green algae, is a single-celled eukaryotic organism intermediate between animals and plants. Euglena contains a rich supply of nutrients, including vitamins, minerals, amino acids, unsaturated fatty acids, chlorophyll, lutein, zeaxanthin, GABA, and 59 other essential nutrients for the human body. The most important component, euglena polysaccharide, is unique to the genus Euglena. Euglena polysaccharide, a linear β-1,3-glucan polysaccharide, serves as an energy storage substance in Euglena cells. my country's National Health and Family Planning Commission approved euglena as a new food ingredient in 2013 (No. 10 of 2013). The European Food Safety Authority also authorized euglena as a novel food in 2020 (2020 / 1820), and in May 2023, an expert panel evaluated and deemed euglena polysaccharide safe as a novel food (2015 / 2283). Studies have shown that naked algae polysaccharides have the activities of improving human immunity, accelerating wound healing, alleviating atopic dermatitis, and inhibiting influenza viruses, and have application prospects in the food and medical fields.

[0004] Existing patents for improving hyperuricemia, such as CN110477232A, disclose a gout-treating euglena beverage and its preparation method, which relate to the field of beverage technology. The beverage prepared by combining euglena with turmeric, ginseng extract, and licorice has the effect of improving hyperuricemia in the short term. CN110101082A discloses a functional food with the dual effects of lowering uric acid and anti-allergy, which relates to the field of functional foods. The effective ingredients include anserine, euglena, egg membrane collagen, and plant extracts. Although the above-mentioned technology proves that the relevant food or beverage has the effect of improving hyperuricemia by combining euglena with other types of functional active substances, it still has the following shortcomings: ① The improvement effect of a single ingredient - euglena on hyperuricemia has not been confirmed; ② Compared with a single type of food, the preparation process of a beverage and a food composed of multiple active ingredients is more complicated and the cost is higher; ③ High uric acid can cause damage to the kidneys, but there is no evidence in the above schemes to show that euglena can protect the kidneys from uric acid damage while lowering uric acid.

[0005] Therefore, it is necessary to develop an application of euglena and its products in improving hyperuricemia. Summary of the Invention

[0006] In order to overcome the defects in the prior art, a method for improving hyperuricemia using euglena and its products is provided.

[0007] The present invention is achieved through the following solutions:

[0008] Disclosed is an application of euglena and products thereof in improving hyperuricemia. The euglena and products thereof are used for improving hyperuricemia.

[0009] The euglena and its products improve hyperuricemia by lowering uric acid and protecting the kidney from damage by uric acid and uric acid-lowering drugs.

[0010] The euglena and its products are used for regulating intestinal flora.

[0011] The euglena and its products have an additive effect on the uric acid-lowering effect of the drug febuxostat.

[0012] The algae and its products regulate the intestinal flora by promoting the growth of probiotic flora in the intestine and inhibiting the growth of harmful flora in the intestine, thereby promoting the decomposition and metabolism of purine and uric acid in the intestine and regulating uric acid metabolism.

[0013] The product of the euglena is an intracellular component of the euglena: euglena polysaccharide.

[0014] The Euglena is a powdery Euglena powder obtained by culturing, harvesting and drying Euglena cells.

[0015] The euglena polysaccharide is powdery euglena polysaccharide obtained by extracting, purifying and drying euglena cells.

[0016] The euglena polysaccharide is obtained by extracting euglena cells through acid, alkali, phosphate buffer, sodium lauryl sulfate, chloroform, methanol or ethanol.

[0017] The naked algae cells are cultured in one or more of the following ways: photoautotrophic, mixed culture or heterotrophic culture.

[0018] The beneficial effects of the present invention are:

[0019] The present invention provides a new method for treating patients with hyperuricemia. The euglena and euglena polysaccharide in the present invention improve hyperuricemia by lowering uric acid and protecting the kidneys from uric acid damage. They also regulate intestinal flora by promoting the growth of probiotics and inhibiting the growth of harmful bacteria, promoting the catabolism of purines and uric acid in the intestines, and regulating uric acid metabolism. The uric acid-lowering effects of euglena polysaccharide and febuxostat are additive. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 is the uric acid value in the serum of mice in different treatment groups in Example 1;

[0021] Figure 2 is the creatinine value in the serum of mice in different treatment groups in Example 1;

[0022] Figure 3 These are photos of the kidneys of mice in different treatment groups in Example 1;

[0023] Figure 4 HE staining of kidney tissues of mice in different treatment groups in Example 1;

[0024] Figure 5 Schematic diagram of PCA analysis of intestinal flora of mice at OUT levels in different treatment groups in Example 1;

[0025] Figure 6 Schematic diagram of PCoA analysis of intestinal flora of mice at different OUT levels in different treatment groups in Example 1

[0026] Figure 7 This is a schematic diagram of the one-way ANOVA of the intestinal flora composition of the negative control group and the different doses of Euglena groups at the genus level in Example 1;

[0027] Figure 8 This is a schematic diagram of the one-way ANOVA of the intestinal flora composition of mice in the negative control group and different doses of euglena polysaccharide groups at the genus level in Example 1;

[0028] Figure 9 This is a schematic diagram of the one-way ANOVA of the intestinal flora composition of mice in the different doses of euglena polysaccharide groups and the different doses of euglena groups at the genus level in Example 1;

[0029] Figure 10 is the uric acid value in the serum of mice in different treatment groups in Example 2;

[0030] Figure 11 is the creatinine value in the serum of mice in different treatment groups in Example 2;

[0031] Figure 12 is the urea nitrogen value in the serum of mice in different treatment groups in Example 2;

[0032] Figure 13 This is the HE staining image of kidney tissue of mice in different treatment groups in Example 2. DETAILED DESCRIPTION

[0033] The preferred embodiments of the present invention are further described below:

[0034] Disclosed is an application of euglena and products thereof in improving hyperuricemia. The euglena and products thereof are used for improving hyperuricemia.

[0035] The euglena and its products improve hyperuricemia by lowering uric acid and protecting the kidney from damage by uric acid and uric acid-lowering drugs.

[0036] The euglena and its products are used for regulating intestinal flora.

[0037] The euglena and its products have an additive effect on the uric acid-lowering effect of the drug febuxostat.

[0038] The algae and its products regulate the intestinal flora by promoting the growth of probiotic flora in the intestine and inhibiting the growth of harmful flora in the intestine, thereby promoting the decomposition and metabolism of purine and uric acid in the intestine and regulating uric acid metabolism.

[0039] The product of the euglena is an intracellular component of the euglena: euglena polysaccharide.

[0040] The Euglena is a powdery Euglena powder obtained by culturing, harvesting and drying Euglena cells.

[0041] The euglena polysaccharide is powdery euglena polysaccharide obtained by extracting, purifying and drying euglena cells.

[0042] The euglena polysaccharide is obtained by extracting euglena cells through inorganic or organic reagents such as acid, alkali, phosphate buffer, sodium lauryl sulfate, chloroform, methanol or ethanol.

[0043] The naked algae cells are cultured in one or more of the following ways: photoautotrophic, mixed culture or heterotrophic culture.

[0044] Based on the above, two groups of animal experiments were conducted using ICR male mice as an animal model, with allopurinol and febuxostat as two uric acid-lowering drugs as positive controls (see Examples 1 and 2, respectively). Hyperuricemia modeling and drug administration were performed by gavage, and blood was collected regularly to detect uric acid, creatinine, and uric acid nitrogen levels in the serum of mice after administration. The structure of intestinal microorganisms in the colon of mice after sacrifice and dissection was analyzed.

[0045] Example 1 Effects of different doses of Euglena and Euglena polysaccharide on hyperuricemia model mice

[0046] Six-week-old ICR male mice were purchased and raised for one week to adapt to the environment. After one week, the mice were randomly divided into 7 groups, 8 mice in each group, for a total of 56 mice; namely, blank control group, negative control group, positive drug (allopurinol) group, high-dose naked algae group, low-dose naked algae group, high-dose naked algae polysaccharide group, and low-dose naked algae polysaccharide group. Adaptive feeding was carried out for one week with natural ventilation and constant temperature and humidity of 23-25℃. Hyperuricemia modeling was then carried out for another week (except for the blank control group). Normal diet was fed daily. Blood was collected every 10 days to monitor the levels of uric acid and creatinine in the serum. After four weeks of gavage, the mice were dissected, the kidneys were taken for photographs, and the tissues were stained with HE.

[0047] Modeling method: Use 300 mg / kg hypoxanthine + 300 mg / kg potassium oxalate for modeling, prepare 60 mg / mL hypoxanthine + 0.5% potassium oxalate suspension, mix 1:1 before use, and administer by gavage. The dosage is based on the dosage volume (mL) = mouse body weight (g) / 100 mL.

[0048] Administration method: The blank control group and the negative control group were both gavaged with 0.5% potassium oxadiazine suspension; the high-dose and low-dose groups of Euglena were gavaged with 408 mg / kg and 204 mg / kg, respectively (Eulegala powder was mixed with 0.5% potassium oxadiazine suspension in a ratio of 1:1 before use); the high-dose and low-dose groups of Euglena polysaccharide were gavaged with 408 mg / kg and 204 mg / kg, respectively (Eulegala polysaccharide powder was mixed with 0.5% potassium oxadiazine suspension in a ratio of 1:1 before use); the positive drug group was gavaged with 5 mg / kg of allopurinol (allopurinol was mixed with 0.5% potassium oxadiazine suspension in a ratio of 1:1 before use); each treatment group was administered with the drug continuously for 30 days.

[0049] (1) Effects of different doses of Euglena and Euglena polysaccharides on uric acid and creatinine levels in mouse serum: Figure 1-2 With Table 1. Figure 1As shown, compared to the negative control group, the uric acid levels in the serum of mice in both the high-dose and low-dose euglena groups, as well as the high-dose and low-dose euglena groups, decreased. Table 1 shows the extent of the decrease in uric acid levels in the serum of mice in each treatment group compared to the negative control group. As shown in Table 1, the decrease in uric acid levels in the serum of mice in the different euglena dose groups was greater than that in the euglena group at the same dose. This indicates that both euglena and euglena polysaccharide can reduce uric acid levels in mouse serum, and that euglena polysaccharide is more effective in lowering uric acid than euglena at the same dose.

[0050] Table 1

[0051]

[0052] The creatinine content in mouse serum reflects the degree of kidney damage in mice. The higher the creatinine content, the greater the degree of kidney damage. The effects of different doses of Euglena and Euglena polysaccharides on the creatinine content in mouse serum are shown in Figure 2 .Depend on Figure 2 The results show that the mean serum creatinine levels in the positive drug groups at each sampling point were the highest, indicating that uric acid-lowering drugs can damage the mouse kidneys. Compared with the negative control group and the positive drug group, the serum creatinine levels in the different doses of Euglena and Euglena polysaccharide groups were significantly lower. This suggests that while the positive drug allopurinol can significantly reduce serum creatinine levels in mice, it can also cause significant damage to the mouse kidneys. Euglena and Euglena polysaccharide can significantly reduce serum uric acid levels in mice and effectively protect the mouse kidneys from uric acid damage.

[0053] (2) Protective effects of different doses of Euglena and Euglena polysaccharide on the kidneys of hyperuricemia model mice: The mice were dissected after the oral administration in Example 1, and the kidneys of the mice in each treatment group were photographed and HE staining of the kidney tissue was performed to analyze the renal tissue lesions of the mice. The results are shown in Figure 3 and Figure 4 .Depend on Figure 3 It can be seen from the appearance that the kidney tissues of the mice in the negative control group and the positive drug group were white, and the epidermal wrinkles were significantly more than those in the blank control group; compared with the negative control group, the kidney tissues of the positive drug group were whiter and the epidermal wrinkles were more, while the kidneys of the mice in the various doses of Euglena and Euglena polysaccharide groups were bright red, and the epidermal wrinkles were not obvious. Figure 4 As shown (ag represent HE-stained photographs of mouse kidney tissue in the blank control group, negative control group, positive drug group, high-dose euglena group, low-dose euglena group, high-dose euglena group, and low-dose euglena group, respectively), the degree of renal pathological changes in each treatment group was as follows: blank control group ≈ high-dose euglena group ≈ high-dose euglena group ≤ low-dose euglena group ≤ low-dose euglena group < negative control group < positive drug group. This suggests that, compared to allopurinol, euglena and euglena can effectively protect the kidneys from uric acid damage while lowering uric acid.

[0054] (3) Effects of Euglena and Euglena polysaccharide on the intestinal flora of hyperuricemia model mice: After the oral administration in Example 1, the mice were dissected and the colon was taken for intestinal flora detection and analysis. First, PCA analysis of the intestinal flora community at the OUT level was performed, and the results are shown in Figure 5 .Depend on Figure 5 It can be seen that (NC is the blank control group, MC is the negative control group, AP is the positive drug group, EH and EL are high-dose and low-dose euglena groups, PH and PL are high-dose and low-dose euglena polysaccharide groups, respectively), the blank control group and the negative control group are significantly separated, and the different doses of euglena groups and different doses of euglena polysaccharide groups are also significantly separated from the negative control group. Subsequently, PCoA analysis of the intestinal flora community at the OUT level was performed, and the results are shown in Figure 6 .Depend on Figure 6 It can be seen that (NC is the blank control group, MC is the negative control group, AP is the positive drug group, EH and EL are high-dose and low-dose euglena groups, PH and PL are high-dose and low-dose euglena polysaccharide groups, respectively), the first principal coordinate PC1 explains 8.35% of the total variation, the PC2 axis explains 7.35% of the intestinal community variation, the blank control group and the negative control group are significantly separated, and the principal component regions of the different doses of euglena groups and different doses of euglena polysaccharide groups are basically separated from the negative control group, indicating that there are differences in the intestinal flora. The variance analysis of the intestinal flora composition of different treatment groups at the genus level is shown in Figure 7-9 .Depend on Figure 7 It can be seen that (NC is the blank control group, MC is the negative control group, EH and EL are the high-dose and low-dose euglena groups, respectively) that compared with the negative control group, the abundance of probiotics such as Hungateiclostridiaceae, Atopobiaceae, and DTU014 in the intestines of mice in the euglena group was significantly increased, while the abundance of harmful bacteria such as Psedoxanthomonas and Monoglobus was significantly decreased; Figure 8 It can be seen that (NC is the blank control group, MC is the negative control group, PH and PL are the high-dose and low-dose algae polysaccharide groups, respectively), the abundance of Faecalibaculum in the intestines of mice in the algae polysaccharide group was significantly reduced compared with the negative control group. Figure 9 It can be seen that (NC is the blank control group, MC is the negative control group, EH and EL are the high-dose and low-dose euglena groups, PH and PL are the high-dose and low-dose euglena polysaccharide groups, respectively), compared with the euglena polysaccharide group, the abundance of Atopobiaceae and Ileibacterium in the euglena group was significantly increased, and the abundance of Faecalibaculum was significantly decreased.

[0055] Example 2 Effects of different doses of euglena polysaccharide on hyperuricemia model mice

[0056] The results of Example 1 have confirmed that the uric acid-lowering effect of Euglena polysaccharide is better than that of Euglena. Allopurinol, as a positive drug, has side effects on kidney tissue while lowering uric acid. However, the side effects of febuxostat on the kidney while lowering uric acid are far less than those of allopurinol. Therefore, in order to better verify the results of Example 1, Example 2 was carried out. Six-week-old ICR male mice were purchased and raised for a week to adapt to the environment. After one week, the mice were randomly divided into 8 groups, 8 mice in each group, for a total of 64 mice; namely, a blank control group, a negative control group, a positive drug (febuxostat) group, groups with different doses of Euglena polysaccharide (a total of four groups), and a group mixed with Euglena polysaccharide and febuxostat. The mice were adapted for one week with natural ventilation and kept at a constant temperature and humidity of 23-25°C. The hyperuricemia model was then established for another week (except for the blank control group). After one week of modeling, the mice were gavage-administered for 30 days and fed a normal diet daily. Blood was collected every 10 days to monitor the levels of uric acid, creatinine, and uric acid nitrogen in the serum. Four weeks after oral administration, the mice were dissected, and the kidneys were taken for photographs and HE staining.

[0057] Modeling method: same as Example 1.

[0058] Administration method: The blank control group and the negative control group were both gavaged with 0.5% potassium oxazide suspension; the different doses of euglena groups were gavaged with 200 mg / kg, 400 mg / kg, 800 mg / kg, and 1600 mg / kg, respectively (euglena powder was mixed with 0.5% potassium oxazide suspension in a ratio of 1:1 before use); the euglena and febuxostat mixed group was gavaged with 1600 mg / kg euglena + 10.2 mg / kg febuxostat (euglena powder, febuxostat powder and 0.5% potassium oxazide suspension in a ratio of 1:1 before use); the positive drug group was gavaged with 10.2 mg / kg febuxostat (febuxostat was mixed with 0.5% potassium oxazide suspension in a ratio of 1:1 before use); each treatment group was continuously administered for 30 days.

[0059] (1) Effects of different doses of algae polysaccharide on the levels of uric acid, creatinine and urea nitrogen in mouse serum: Figure 10-12 With Table 2. Figure 10As can be seen, compared to the negative control group, uric acid levels decreased in the different euglena dose groups and the euglena and febuxostat combination group. Table 2 shows the rate of decrease in uric acid levels in the serum of mice in each treatment group compared to the negative control group. As shown in Table 2, with increasing euglena dose, the magnitude of the decrease in uric acid levels in the serum of mice in each treatment group also increased. In addition, the uric acid decrease rate in the euglena and febuxostat combination group was higher than that in the febuxostat group. This suggests that higher doses of euglena are associated with greater uric acid-lowering effects, and that the uric acid-lowering effects of euglena and febuxostat are additive.

[0060] Table 2

[0061]

[0062] Serum creatinine levels in mice in each treatment group were shown in Figure 11 .Depend on Figure 11 The results show that the mean serum creatinine levels of mice in the positive drug groups at all sampling points were the highest, indicating that febuxostat can damage the mouse kidneys. Compared with the negative control and positive drug groups, the serum creatinine levels of mice in the different doses of euglena polysaccharide groups were significantly lower. On day 20, the creatinine level in the 1600mg / Kg euglena polysaccharide + 10.2mg / Kg febuxostat group was lower than that in all other groups, indicating that the 1600mg / Kg dose of euglena polysaccharide can effectively protect against kidney damage caused by hyperuricemia and the positive drug febuxostat.

[0063] The level of urea nitrogen in serum is also an important indicator of kidney damage. Figure 12 The positive drug groups all had the highest serum urea nitrogen values, indicating that febuxostat can cause kidney damage. The 1600mg / kg euglena polysaccharide group had lower serum urea nitrogen values ​​than all other experimental groups. The 1600mg / kg euglena polysaccharide + 10.2mg / kg febuxostat group had much lower urea nitrogen values ​​than the positive drug group, indicating that the 1600mg / kg dose of euglena polysaccharide can effectively reduce the degree of kidney damage caused by high uric acid and the positive drug febuxostat.

[0064] (2) Protective effects of different doses of algae polysaccharide on the kidneys of hyperuricemia model mice: Figure 13It can be seen that (ah represent the HE staining photos of mouse kidney tissue in the blank control group, negative control group, positive drug group, 200 mg / kg euglena group, 400 mg / kg euglena group, 800 mg / kg euglena group, 1600 mg / kg euglena group, and 1600 mg / Kg euglena + 10.2 mg / Kg febuxostat group, respectively), considering the overall comprehensive conditions of the lesions from mild to severe: blank group ≤ 1600 mg / kg euglena group ≤ 800 mg / kg euglena group ≈ 400 mg / kg euglena group ≤ 1600 mg / Kg euglena + 10.2 mg / Kg febuxostat group ≤ 200 mg / kg euglena group ≈ negative control group < febuxostat group (< represents significant difference, ≈ represents little difference, ≤ represents difference). It shows that the dose of euglena polysaccharide is positively correlated with the alleviating effect on renal damage caused by hyperuricemia, and euglena polysaccharide can reduce the degree of renal damage induced by the positive drug febuxostat.

[0065] The application of the present invention's Euglena and its products in improving hyperuricemia can prove that Euglena and Euglena polysaccharide have the function of lowering uric acid and protecting the kidney from uric acid damage, laying a foundation for the application of Euglena and Euglena polysaccharide in the field of treating hyperuricemia in the future.

[0066] Although the technical solutions of the present invention have been described and listed in detail, it should be understood that it is obvious to those skilled in the art to make modifications to the above embodiments or adopt equivalent alternatives. These modifications or improvements made without departing from the spirit of the present invention are within the scope of protection claimed by the present invention.

Claims

1. A use of Euglena and its products in improving hyperuricemia, characterized by: The euglena and its products are used for improving hyperuricemia.

2. The use of a Euglena and its products in improving hyperuricemia according to claim 1, characterized in that: The euglena and its products improve hyperuricemia by lowering uric acid and protecting the kidney from damage by uric acid and uric acid-lowering drugs.

3. The use of a Euglena and its products in improving hyperuricemia according to claim 1, characterized in that: The euglena and its products are used for regulating intestinal flora.

4. The use of a Euglena and its products in improving hyperuricemia according to claim 1, characterized in that: The euglena and its products have an additive effect on the uric acid-lowering effect of the drug febuxostat.

5. The use of a Euglena and its products in improving hyperuricemia according to claim 3, characterized in that: The algae and its products regulate the intestinal flora by promoting the growth of probiotic flora in the intestine and inhibiting the growth of harmful flora in the intestine, thereby promoting the decomposition and metabolism of purine and uric acid in the intestine and regulating uric acid metabolism.

6. The use of a Euglena and its products in improving hyperuricemia according to claim 1, characterized in that: The product of the euglena is an intracellular component of the euglena: euglena polysaccharide.

7. The use of a Euglena and its products in improving hyperuricemia according to claim 6, characterized in that: The Euglena is a powdery Euglena powder obtained by culturing, harvesting and drying Euglena cells.

8. The use of a Euglena and its products in improving hyperuricemia according to claim 6, characterized in that: The euglena polysaccharide is powdery euglena polysaccharide obtained by extracting, purifying and drying euglena cells.

9. The use of a Euglena and its products in improving hyperuricemia according to claim 8, characterized in that: The euglena polysaccharide is obtained by extracting euglena cells through acid, alkali, phosphate buffer, sodium lauryl sulfate, chloroform, methanol or ethanol.

10. The use of a Euglena and its products in improving hyperuricemia according to any one of claims 6 to 9, characterized in that: The naked algae cells are cultured in one or more of the following ways: photoautotrophic, mixed culture or heterotrophic culture.

Images